Sign up to save your podcasts
Or
Share Dr. Jen Rogers on the Use of CB-CAPs to Assess Disease Activity in SLE
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dr. Jen Rogers on the Use of CB-CAPs to Assess Disease Activity in SLE
What is the Type 1 vs Type 2 Lupus Model? How does it shape the care and management of lupus patients? And what impact does it have on the future of drug development to address Type 2 symptoms?
Join Exagen and Dr. Jen Rogers, Director of the Duke Lupus Clinic as she breaks down the abstract, The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE, how the study came to be, and its clinical importance to both providers and patients.
View all episodes
By Exagen PodcastWhat is the Type 1 vs Type 2 Lupus Model? How does it shape the care and management of lupus patients? And what impact does it have on the future of drug development to address Type 2 symptoms?
Join Exagen and Dr. Jen Rogers, Director of the Duke Lupus Clinic as she breaks down the abstract, The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE, how the study came to be, and its clinical importance to both providers and patients.